This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro and Sabrina Tavernise. Twenty minutes a day, five days a week, ready by 6 a.m.Listen to this podcast in New York Times Audio, our new iOS app for news subscr… read more
When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.
But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.
What is the story behind this new drug?
Guest: Pam Belluck, a health and science writer for The New York Times.
Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
Educational
Interesting
Funny
Agree
Love
Wow
Connect with listeners
Podcasters use the RadioPublic listener relationship platform to build lasting connections with fans
Yes, let's begin connectingFind new listeners
Understand your audience
Engage your fanbase
Make money